The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies.
Katherine L BeaversonDaria JulkowskaMary Catherine V LetinturierAnnemieke Aartsma-RusJennifer AustinJuan BuerenSimon FrostMisako HamamuraJane LarkindaleGreg LaRosaRita MagenheimAnnamaria MericoAnna Maria Gerdina PasmooijVinciane PirardNicholas Ekow ThomfordMichihiko WadaDurhane Wong-RiegerAdam L HartmanPublished in: Therapeutic advances in rare disease (2023)
The Chrysalis Task Force identified factors attributable to rare disease research and development that may be of interest to and actionable by funders, academic researchers, patients and their families, companies, regulators, and payers in the medium term to short term. By addressing the identified challenges, involved parties may seek solutions to significantly advance the research and development of treatments for rare diseases.